Welcome to our dedicated page for Alpha Teknova news (Ticker: TKNO), a resource for investors and traders seeking the latest updates and insights on Alpha Teknova stock.
Alpha Teknova, Inc. reports recurring financial and operating updates as a life-sciences reagent manufacturer serving therapy, vaccine and molecular-diagnostics workflows. The company organizes revenue around Lab Essentials and Clinical Solutions, with products that include agar plates, microbial culture and cryopreservation media, buffers, molecular biology reagents and water used across research-use and GMP production settings.
Company news commonly covers quarterly and annual results, revenue guidance, segment performance, Clinical Solutions customer activity, cash use, borrowings and free cash flow. Updates also describe Teknova’s modular manufacturing platform and its role in supplying foundational reagents for genomics, synthetic biology, molecular diagnostics and emerging therapeutic modalities.
Teknova (Nasdaq: TKNO) will participate in two upcoming investor conferences: the Stephens Annual Investment Conference from November 15-17, 2022, and the Piper Sandler 34th Annual Healthcare Conference from November 29-December 1, 2022. At these events, CEO Stephen Gunstream and CFO Matt Lowell will discuss company highlights, product offerings, and market opportunities. Live webcasts will be available on the company's website for 90 days post-event. Teknova focuses on providing custom reagents for drug therapies, vaccines, and diagnostics.
Alpha Teknova, Inc. (Nasdaq: TKNO) will report its third quarter financial results for the period ending September 30, 2022, on November 9, 2022. A conference call and webcast will follow at 4:30 p.m. ET, accessible via the company’s Investor Relations page. Teknova specializes in providing critical reagents for drug therapies and diagnostics, emphasizing agility and customization in delivering high-quality products. The company's offerings include cell culture media and purification buffers for various applications, such as mRNA therapeutics and genomics.
Alpha Teknova (Nasdaq: TKNO) announced an Early Access Program for two innovative products aimed at enhancing gene therapy processes: an Anion Exchange Buffer Screening Kit and a Functional Reporter Assay. These products are still in development and focus on improving AAV therapy workflows. Additionally, the company revealed it will launch a WFI Quality Water product available online in November 2022. The goal is to streamline development and increase product purity for AAV gene therapy developers.
Alpha Teknova, a leading provider of critical reagents, announced that CEO Stephen Gunstream will present at the 2022 Cell & Gene Meeting on the Mesa on October 12, 2022. The presentation, scheduled for 5:45 p.m. PT in Carlsbad, California, will focus on the company's growth strategy and updates in their gene therapy product development. This three-day conference, organized by the Alliance for Regenerative Medicine, gathers industry executives to discuss advancements in cell and gene therapies. A live broadcast will be available for registered participants.
Alpha Teknova, Inc. (Nasdaq: TKNO), a leader in critical reagents for drug therapies and vaccines, will join the Morgan Stanley 20th Annual Global Healthcare Conference from September 12-14, 2022, in New York.
On September 13, 2022, at 7:20 AM ET, CEO Stephen Gunstream and CFO Matt Lowell will engage in a fireside chat discussing company highlights, product portfolio, and market trends. A live audio webcast will be available on Teknova's Investor Relations website for 90 days post-event.
Alpha Teknova reported a total revenue of $11.7 million for Q2 2022, representing a 41% year-over-year increase. The company maintains a cash position of $64.7 million to support ongoing growth investments and has adjusted its 2022 revenue outlook to $38-42 million. Although they experienced healthy demand, Teknova acknowledges potential revenue slowdown in H2 2022 due to biopharma customers deferring purchases. Gross profit reached $5.2 million, with a 44.9% gross margin, despite increased operating expenses of $11.9 million and a net loss of $6.2 million.
HOLLISTER, Calif., Aug. 01, 2022 – Alpha Teknova, Inc. (Nasdaq: TKNO) announced it will report its financial results for Q2 2022 on August 10, 2022, after market close. A conference call and webcast will follow at 4:30 p.m. ET. Teknova specializes in providing critical reagents for drug therapies, vaccines, and diagnostics, aiming to expedite clinical breakthroughs with a focus on custom solutions and fast delivery. Its products are essential across various applications, including cell and gene therapy and mRNA therapeutics.
Alpha Teknova, a provider of critical reagents for drug therapies and molecular diagnostics, will participate in the William Blair 42nd Annual Growth Stock Conference from June 6 to 9, 2022, in Chicago, IL. CEO Stephen Gunstream and CFO Matt Lowell will present on June 8 at 4:20 p.m. ET, discussing the company’s highlights, product portfolio, and market opportunities. A live audio webcast will be available on their Investor Relations website for 90 days post-event.
In Q1 2022, Teknova reported total revenue of $11.1 million, a 23% increase year-over-year. Excluding Sample Transport revenue, the increase was 37%. The company achieved a cash position of $76.5 million, supporting its growth strategy and expansion efforts, including a new manufacturing facility expected to be operational by year-end. However, the company reported a net loss of $5.5 million and operating expenses that rose to $11.2 million, reflecting increased hiring and public company costs. The 2022 revenue outlook anticipates $45 million to $48 million.
Alpha Teknova, Inc. (TKNO) will announce its Q1 financial results for the period ending March 31, 2022, on May 11, 2022. A conference call and webcast will occur at 4:30 p.m. ET the same day. The call can be accessed via the Investor Relations section of Teknova's website or by dialing dedicated numbers for domestic and international participants. Teknova specializes in providing critical reagents to support drug therapies, vaccines, and diagnostics, emphasizing customized products for accelerated clinical breakthroughs.